Potassium News and Research

RSS

RLY5016 potassium binder helps to regulate hyperkalemia in heart failure patients

Results from a recent phase 2b clinical trial may provide a new approach to managing excess potassium levels in patients with heart failure and heart failure with chronic kidney disease.

30 Aug 2010

FDA approves Novartis' Tekamlo for treatment of high blood pressure

The US Food and Drug Administration (FDA) approved Tekamlo™ (aliskiren and amlodipine) tablets, a single-pill for the treatment of high blood pressure combining the only approved direct renin inhibitor, Tekturna® (aliskiren), with the widely used calcium channel blocker amlodipine. Tekamlo is approved as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals, and as replacement therapy for patients whose blood pressure is not adequately controlled with either aliskiren or amlodipine alone.

27 Aug 2010

Researchers find two high-fat diets reduce absence epilepsy in children

Two high-fat diets the classic ketogenic and a modified version of the Atkins can reduce and, in some cases, completely eliminate seizures in children with a common seizure disorder known as absence epilepsy, say researchers from Johns Hopkins Children's Center.

27 Aug 2010

Amneal Pharmaceuticals receives FDA approval for Spironolactone HCl tablets

Amneal Pharmaceuticals, LLC is pleased to announce that it has received U.S. FDA approval to manufacture Spironolactone HCl tablets in 25 mg, 50 mg and 100 mg strengths effective July 2, 2010.

26 Aug 2010

Tasigna receives approval for chronic myeloid leukemia in Canada

Tasigna (nilotinib) capsules have been approved with conditions in Canada as a new therapy for patients with CML, in the chronic phase (first phase) of the disease. Patients must be resistant to or intolerant of at least one prior therapy, including (Pr)Gleevec (imatinib mesylate), an established standard of care.

20 Aug 2010

New DNA sequencing method can lead to effective individualized medicine

In experiments with potentially broad health care implications, a research team led by a University of Washington physicist has devised a method that works at a very small scale to sequence DNA quickly and relatively inexpensively.That could open the door for more effective individualized medicine, for example providing blueprints of genetic predispositions for specific conditions and diseases such as cancer, diabetes or addiction.

17 Aug 2010

Cumberland Pharmaceuticals reports 9% increase in second quarter 2010 net revenue

Cumberland Pharmaceuticals Inc. ,a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announces financial results for the second quarter ending June 30, 2010, and provides revenue guidance for full year 2010.

17 Aug 2010

Study examines comparative value of different blood pressure lowering medications

Expensive brand-name medications to lower blood pressure are no better at preventing cardiovascular disease than older, generic diuretics, according to new long-term data from a landmark study.Paul Whelton, MB, MD, MSc, reported the results on Aug. 13 at the plenary session of the China Heart Congress and International Heart Forum in Beijing. Whelton is president and CEO of Loyola University Health System and chairman of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heat Attack Trial (ALLHAT), which has examined the comparative value of different blood pressure-lowering medications.

13 Aug 2010

Perrigo fourth-quarter fiscal 2010 net sales up 22%

Perrigo Company today announced results for its fourth quarter and full year ended June 26, 2010.

12 Aug 2010

FDA advisory committee votes in favor of Ezogabine

The U.S. Food and Drug Administration advisory committee voted unanimously that clinical studies had provided substantial evidence of the effectiveness of Ezogabine (known as Retigabine outside of the U.S.) as adjunctive treatment for adults with partial-onset seizures.

12 Aug 2010

FDA accepts Salix's XIFAXAN550 sNDA for Priority Review

Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Company's efficacy supplement to the New Drug Application (NDA) for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating.

9 Aug 2010

Acorda second-quarter net loss decreases to $6.8 million

Acorda Therapeutics, Inc. today announced its financial results for the second quarter of 2010.

3 Aug 2010

Merck reports strong bottom-line performance in second quarter

Merck & Co., Inc. today announced financial results for the second quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the second quarter of $0.86, which excludes purchase accounting adjustments, merger-related expenses, restructuring costs and the gain on AstraZeneca's asset option exercise. Second-quarter GAAP EPS was $0.24.

2 Aug 2010

Researchers identify new genetic route to treat epilepsy

New research points to a genetic route to understanding and treating epilepsy. Timothy Jegla, an assistant professor of biology at Penn State University, has identified an ancient gene family that plays a role in regulating the excitability of nerves within the brain.

2 Aug 2010

Shionogi's CUVPOSA receives FDA approval for treatment of chronic severe drooling

Shionogi Inc., a U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. Food and Drug Administration approval of CUVPOSA™ (glycopyrrolate), the first liquid treatment for patients ages 3-16 who suffer from chronic severe drooling associated with neurologic conditions such as cerebral palsy. CUVPOSA™ was designated an Orphan Drug by the FDA.

30 Jul 2010

Teva second-quarter net sales increase 12% to $3.8 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended June 30, 2010.

27 Jul 2010

Burger King to offer breakfast meal that meets BKC's stringent nutrition criteria

Today Burger King Corp. announced it will offer a breakfast meal for children that meets BKC's stringent nutrition criteria for advertised Kids Meals, as defined in its pledge through the Council of Better Business Bureau's Children's Food and Beverage Advertising Initiative.

21 Jul 2010

Acorda Therapeutics awarded $1M C-TRIP grant to support research on GGF2

Acorda Therapeutics, Inc. today announced the National Heart, Lung, and Blood Institute has awarded a $1 million Cardiac Translational Research Implementation Program grant to support research on Glial Growth Factor 2, a novel investigational agent for the treatment of patients with heart failure under development at Acorda.

20 Jul 2010

Mayo Clinic's July issue offers tips on ophthalmology, Alzheimer's and CKD

Here are highlights from the July issue of Mayo Clinic Women's HealthSource. You may cite this publication as often as you wish. Mayo Clinic Women's HealthSource attribution is required.

20 Jul 2010

High blood pressure, diabetes leads to CKD

People with diabetes and high blood pressure need to take care of their kidneys. According to the July issue of Mayo Clinic Women's HealthSource, chronic kidney disease (CKD) is a growing problem in the United States. The most common causes are diabetes and high blood pressure

16 Jul 2010